Company intelligence / Profile preview

TeneoSeven

Newark, California, United States

Ownership: Private
Development stage: Other

Overview

TeneoSeven was a clinical-stage biotechnology company and a subsidiary of Teneobio, focused on developing TNB-383B, a fully human bispecific antibody for the treatment of multiple myeloma. The company's lead candidate, TNB-383B, was designed to simultaneously target BCMA on cancer cells and CD3 on T cells to induce tumor cell killing. TeneoSeven was part of a series of asset-specific companies spun out of Teneobio's antibody discovery platform. In 2021, the company was acquired by AbbVie following the exercise of an exclusive right to acquire the entity based on Phase 1 clinical data.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyAntibodyBiologic
Industry: Biotech

Partnerships

AbbVie

Beyond the preview

Go deeper on TeneoSeven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeneoSeven.

Explore the full profile